Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Biondi, Andrea  [Clear All Filters]
2024
Buldini B, Varotto E, Maurer-Granofszky M, Gaipa G, Schumich A, Brüggemann M, Mejstrikova E, Cazzaniga G, Hrusak O, Szczepanowski M, et al. CD371+ pediatric B-cell acute lymphoblastic leukemia: propensity to lineage switch and slow early response to treatment. Blood. 2024.
Donsante S, Pievani A, Palmisano B, Finamore M, Fazio G, Corsi A, Biondi A, Tomatsu S, Piazza R, Serafini M, et al. Modeling skeletal dysplasia in Hurler syndrome using patient-derived bone marrow osteoprogenitor cells. JCI Insight. 2024;9(5).
2023
Hunger SP, Tran THoa, Saha V, Devidas M, Valsecchi MGrazia, Gastier-Foster JM, Cazzaniga G, Reshmi SC, Borowitz MJ, Moorman AV, et al. Dasatinib with intensive chemotherapy in de novo paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (CA180-372/COG AALL1122): a single-arm, multicentre, phase 2 trial. Lancet Haematol. 2023;10(7):e510-e520.
Förster A, Davenport C, Duployez N, Erlacher M, Ferster A, Fitzgibbon J, Göhring G, Hasle H, Jongmans MC, Kolenova A, et al. European standard clinical practice - Key issues for the medical care of individuals with familial leukemia. Eur J Med Genet. 2023:104727.
Conter V, Valsecchi MGrazia, Cario G, Zimmermann M, Attarbaschi A, Stary J, Niggli F, Pozza LDalla, Elitzur S, Silvestri D, et al. Four Additional Doses of PEG-L-Asparaginase During the Consolidation Phase in the AIEOP-BFM ALL 2009 Protocol Do Not Improve Outcome and Increase Toxicity in High-Risk ALL: Results of a Randomized Study. J Clin Oncol. 2023:JCO2301388.
Caserta C, Nucera S, Barcella M, Fazio G, Naldini MMaria, Pagani R, Pavesi F, Desantis G, Zonari E, D'Angiò M, et al. miR-126 identifies a quiescent and chemo-resistant human B-ALL cell subset that correlates with minimal residual disease. Leukemia. 2023.
Roncareggi S, Girardi K, Fioredda F, Pedace L, Arcuri L, Badolato R, Bonanomi S, Borlenghi E, Cirillo E, Coliva T, et al. A Nationwide Study of GATA2 Deficiency in Italy Reveals Novel Symptoms and Genotype-phenotype Association. J Clin Immunol. 2023.
Nucera S, Sindoni MM, Bugarin C, Villa T, Biondi A, Balduzzi A, Gaipa G. A novel flow-cytometric based method to assess post-HSCT donor chimerism exploiting RNA hybridization. Bone Marrow Transplant. 2023.
Tomasoni C, Pievani A, Rambaldi B, Biondi A, Serafini M. A Question of Frame: The Role of the Bone Marrow Stromal Niche in Myeloid Malignancies. Hemasphere. 2023;7(6):e896.
Biondi M, Tettamanti S, Galimberti S, Cerina B, Tomasoni C, Piazza R, Donsante S, Bido S, Perriello VMaria, Broccoli V, et al. Selective homing of CAR-CIK cells to the bone marrow niche enhances control of the Acute Myeloid Leukemia burden. Blood. 2023.
2022
Zhou Y, Shalhoub RN, Rogers SN, Yu S, Gu M, Fabre MAlice, Quiros PM, Diangson A, Deng W, Anand S, et al. Clonal Hematopoiesis Is Not Significantly Associated with Covid-19 Disease Severity. Blood. 2022.
Perriello VMaria, Rotiroti MCaterina, Pisani I, Galimberti S, Alberti G, Pianigiani G, Ciaurro V, Marra A, Sabino M, Tini V, et al. IL3-zetakine combined with a CD33 costimulatory receptor as a Dual CAR approach for safer and selective targeting of AML. Blood Adv. 2022.
Fazio G, Bresolin S, Silvestri D, Quadri M, Saitta C, Vendramini E, Buldini B, Palmi C, Bardini M, Grioni A, et al. PAX5 fusion genes are frequent in poor risk childhood acute lymphoblastic leukaemia and can be targeted with BIBF1120. EBioMedicine. 2022;83:104224.
2020
Magnani CF, Gaipa G, Lussana F, Belotti D, Gritti G, Napolitano S, Matera G, Cabiati B, Buracchi C, Borleri G, et al. Sleeping Beauty-engineered CAR T cells achieve anti-leukemic activity without severe toxicities. J Clin Invest. 2020.
2019
Portale F, Beneforti L, Fallati A, Biondi A, Palmi C, Cazzaniga G, Dander E, D'Amico G. Activin-A contributes to the definition of a pro-oncogenic bone marrow microenvironment in t(12;21) preleukemia. Exp Hematol. 2019:3717.
Bagnasco F, Caruso S, Andreano A, Valsecchi MGrazia, Jankovic M, Biondi A, Miligi L, Casella C, Terenziani M, Massimino M, et al. Late mortality and causes of death among 5-year survivors of childhood cancer diagnosed in the period 1960-1999 and registered in the Italian Off-Therapy Registry. Eur J Cancer. 2019;110:86-97.
2015
Magnani CFrancesca, Biondi A, Biagi E. Donor-derived CD19-targeted T cells in allogeneic transplants. Curr Opin Hematol. 2015.
2014
Tettamanti S, Biondi A, Biagi E, Bonnet D. CD123 AML targeting by chimeric antigen receptors: A novel magic bullet for AML therapeutics?. Oncoimmunology. 2014;3:e28835.
2013
Magnani CF, Tettamanti S, Maltese F, Turazzi N, Biondi A, Biagi E. Advanced targeted, cell and gene-therapy approaches for pediatric hematological malignancies: results and future perspectives. Front Oncol. 2013;3:106.